8 terminated. 8 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cystoscopic Ablation Via RF Energy Clinical Trial Amphora OAB Device - Overactive Bladder | Phase 1 / Phase 2 | Terminated | Amphora Medical, Inc. | 63 | 2015-02-01 | 2019-05-07 |
| Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients BTX mixed with TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Terminated | UroGen Pharma Ltd. | 3 | 2014-07-01 | 2016-03-01 |
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder Bryophyllum - Overactive Bladder, Urge Urinary Incontinence | Phase 2 / Phase 3 | Terminated | University of Zurich | 9 | 2014-05-01 | 2017-10-26 |
| Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder Botulinum toxin type A, Placebo - Overactive Bladder | Phase 2 | Terminated | Ipsen | 81 | 2008-02-01 | 2019-11-22 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Normal saline (Placebo); botulinum toxin Type A (200U), botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U) - Overactive Bladder | Phase 2 | Terminated | Allergan | 74 | 2007-12-01 | 2015-10-02 |
| ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) ELB245, Tolterodine - Overactive Bladder, Urinary Incontinence | Phase 2 | Terminated | elbion AG | 275 | 2007-02-01 | 2007-08-08 |
| Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients GW679769 - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder | Phase 2 | Terminated | GlaxoSmithKline | 1 | 2006-01-01 | 2015-04-17 |
| NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder type A botulinum toxin - Overactive Bladder | Phase 2 | Terminated | University Hospital, Rouen | 80 | 2003-12-01 | 2015-03-24 |
Urinary Bladder, Overactive (8) · Urinary Incontinence, Urge (2) · Spinal Cord Injuries (1) · Urinary Incontinence (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Lower Urinary Tract Symptoms (8) · Male Urogenital Diseases (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Urinary Bladder Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Urological Manifestations (8) · Urination Disorders (3) · Urinary Incontinence (2) · Central Nervous System Diseases (1) · Nervous System Diseases (1) · Spinal Cord Diseases (1)
Botulinum Toxins, Type A (3) · Saline Solution (1) · Tolterodine Tartrate (1) · abobotulinumtoxinA (1) · casopitant (1)
Allergan (1) · Amphora Medical, Inc. (1) · GlaxoSmithKline (1) · Ipsen (1) · University Hospital, Rouen (1) · University of Zurich (1) · UroGen Pharma Ltd. (1) · elbion AG (1)
Belgium (2) · France (2) · Germany (2) · Canada (1) · Czechia (1) · Egypt (1) · Greece (1) · India (1) · Israel (1) · Italy (1) · Lebanon (1) · Netherlands (1) · Poland (1) · Serbia (1) · Spain (1)
Ami Sidi, Prof MD (1) · Martin Michel, Prof. (1) · Roger Demochowski, MD (1)